Natco Pharma approves financing plan


Natco Pharma Ltd’s corporate board has approved a financing plan that would raise Rs.450 crore by selling shares to investors. These funds will help to pay for company expansion projects as well as the acquisition of technologies to promote future drug launches. Natco is planning on the launches of three major generic medicines, including the MS drug copaxone, the anti-anemia drug revlimid, and the antiviral drug Tamiflu. Natco is still involved in a lawsuit with Teva over the launch of the generic version of copaxone.


Read the source article at

About the Author

Related Posts

Leave a Reply